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ABSTRACT
The CYP2D subfamily is the second most important subfamily of hepatic drug metabolizing
CYPs. In mouse, there are nine CYP2D subfamily members, while humans have only one highly
polymorphic CYP2D member, CYP2D6. siRNA was used to repress the expression of multiple
isoforms of mouse CYP2D in primary mouse hepatocytes with one siRNA construct. Successful
knockdown of CYP function by RNAi may allow for further study of CYP2D function. Q-PCR
demonstrated that male CD-1 mouse primary hepatocytes express Cyp2d10, Cyp2d11, Cyp2d22,
and Cyp2d26; however the male specific and growth hormone-dependent, Cyp2d9, was not
detected. Four different siRNAs were designed; Cyp2d-KD1 and Cyp2d-KD2 target multiple
CYPs while Cyp2d10-Design A and Cyp2d10-Design B only target Cyp2d10. 90% transfection
efficiency with minimal cellular toxicity was achieved when Mirus-TKO transfection reagent
was used. qPCR demonstrated that the construct designed to knockdown every CYP2D isoform,
siRNA-KD1, showed knockdown efficiency of 50-70% and these results were reproducible with
all four CYP2D members tested. Interestingly, a construct designed to knockdown all CYP2D
isoforms except Cyp2d10, siRNA-KD2, induced Cyp2d10 expression 2.5-fold, presumably
because of a compensatory response. Testosterone hydroxylation activity, tamoxifen metabolism
and CYP2D activity were tested in scrambled and Cyp2d-KD1 siRNA treated hepatocytes using
TLC, HPLC and CYP2D6-Glo(tm) Screening Systems respectively. No metabolites differences
were observed.

Overall, this study may provide a new tool for determining CYP2D’s role in

xenobiotic metabolism, valuable information on how to design siRNA studies for silencing CYP
subfamilies and ultimately may help in silencing mouse CYP2D’s within a humanized CYP2D6
mouse model.
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BACKGROUND

Cytochrome P450s (CYPs) are enzymes that participate in many important metabolic
processes including the detoxification of endogenous and exogenous chemicals. They
perform a wide spectrum of reactions including hydroxylation, N-oxidation,
sulfoxidation, epoxidation, N-, S-, and O-dealkylation, peroxidation, deamination,
desulfuration and dehalogenation with the general purpose of making the substance more
polar and water soluble. P450s metabolize endobiotics, such as steroids, bile acids, fatty
acids, and prostaglandins, as well as xenobiotic compounds. Ultimately, the metabolism
of chemicals by CYPs (phase Ι) prepares the chemicals for phase ΙΙ conjugation (Cooper
et al, 1965; Imai et al 1977; Champion et al, 1982; Nelson et al. 1996, Lewis, 1996;
Bertz & Granneman 1997, Munro et al, 2007).

For nomenclature purposes, the enzymes and genes encoding CYPs contain an Arabic
numeral indicating the gene family, followed by a capital letter indicating the subfamily,
and another numeral for the individual enzyme or gene. The italicized name refers to the
gene. For example, CYP2D6 is the gene that encodes the enzyme CYP2D6 which is in
family 2, subfamily D and the 6th isoform. Human CYP names are capitalized (CYP2D6)
and mouse CYP names are typically kept in lowercase (i.e. Cyp2d9). CYPs sequences
having greater than 40% identical at the amino acid level belong to the same family.
While those that having sequences that are greater than 55% identical are in the same
subfamily. There are now more than 7700 named cytochrome P450 sequences. There is a
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Nomenclature Committee that keeps track of and assigns new names (Nelson D.R. et al
2004). The human CYP genes have been arranged into 18 families, 43 subfamilies, and
57 isoforms; the mouse CYP genes have bee
been
n arranged into 13 families, 43 subfamilies,
and 102 isoforms (Nelson, 1999, Nelson D.R. et al, 1993, 2004).

In humans and mice, CYPs of families 11-3 are the primary ones responsible
nsible for
xenobiotic metabolism, and m
mutations in them can affect drug metabolism
lism (Nelson,
1999). The activity of various CYP isozymes may also be increased or decreased by
either inducing the biosynthesis of an isozyme or by directly inhibiting the activity of the
CYP. This is a major source of adverse drug interactions, in which a change in a CYP’s
activity affects the metabolism and detoxification of multiple drugs. An example of drugdrug
drug interaction, the nonsteroidal antiestrogen tamoxifen is used for breast cancer
treatment and metabolized mainly by CYP2D6
CYP2D6. Patients using CYP2D6 inhibitors
(antidepressants; Fluoxetine paroxetine
paroxetine, bupropion, and duloxetine ) can be at potential
risk because of reduce tamoxifen efficacy
efficacy.

The CYP2D subfamily plays an important role in the metabolism of xenobiotics and
endobiotics. CYP2D isoforms have been identified in several mammalian species and are
involved in the monooxygenation of various chemicals including antidepressants (e.g.
desipramine), -blockers (e.g. propranolol), antiarrhythmics (e.g. sparteine), and others
(e.g. dextromethorphan and methadone) in the liver (Eichelbaum and Gross, 1990;
Gonzalez, 1996). In humans, only one functional isoform, CYP2D6,
6, is expressed in
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various tissues including the liver, kidney, brain, placenta, breast, and lung (Niznik et al.,
1990; Romkes-Sparks et al., 1994; Carcillo et al., 1996; Hakkola et al., 1996; Guidice et
al., 1997; Huang et al., 1997 and Nishimura et al., 2003). On the other hand, in mice,
nine isoforms (Cyp2d9, Cyp2d10, Cyp2d11, Cyp2d12, Cyp2d13, Cyp2d22, Cyp2d26,
Cyp2d34 and Cyp2d40) have been identified by genomic analysis. It is thought that
mouse Cyp2d22 is the ortholog of human CYP2D6 (Blume et al 2000 and Singh et al
2009).

In general, drug-metabolizing P450s are expressed at high levels in the liver, which
controls the systemic levels of most drugs, xenobiotics and their metabolites. Orally
administered xenobiotics pass through the intestine first before reaching the liver and has
the capacity to metabolize many of these compounds through pathways mediated by
P450s, including CYP2D6 (Prueksaritanont et al., 1995; Madani et al., 1999). The
intestine may contribute to bioavailability and activation or deactivation of many
xenobiotics. In addition to liver and intestine, CYP2D6 is expressed in kidney, and
kidney tissue injury by some xenobiotics is dependent on renal P450 metabolism to toxic
metabolites (Liu and Baliga, 2003; Liu et al., 2003). CYP2D6 is expressed in human
brain (Siegle et al., 2001; Chinta et al., 2002; Miksys et al., 2002), suggesting the
possibility of an endogenous function of CYP2D6 in the metabolism of neurochemicals.
Although CYP2D6 activity has not been characterized yet in human brain, the kinetics of
CYP2D-mediated dextromethorphan O-demethylase activity has been well described in
rat brain tissues (Tyndale et al., 1999).
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In mouse, Cyp2d10, Cyp2d11, Cyp2d13, Cyp2d22, Cyp2d26, and Cyp2d40 are
expressed in liver. Cyp2d12, Cyp2d13, and Cyp2d34 are expressed in colon while
Cyp2d12 is only expressed in kidney (Mouse Genome Informatics, 2010) (Table 1).
Comparing CYP2Ds in mouse and human CYP2D6, recent studies showed that the cellspecific expression of human CYP2D6 in liver, kidney, and intestine in humanized mice
was similar to that reported in humans. While the expression patterns of mouse CYP2D
proteins were similar to those in humans in liver and kidney but not in intestine.
Moreover, human CYP2D6 was not detected in brain of transgenic mice while mouse
CYP2D proteins were detected in brain (Ai-Ming and Robert, 2006).

Table (1): Tissue expression of mouse Cyp2ds

a

CYP2D(s)

Organ expression

Cyp2d9

Liver/ Male specific

Cyp2d10

Liver a

Cyp2d11

Liver a

Cyp2d12

Colon/Kidney a

Cyp2d13

Liver/colon a

Cyp2d22

Liver a

Cyp2d26

Liver a

Cyp2d34

Colon a

Cyp2d40

Liver a

Information from Mouse Genome Informatics
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The CYP2D subfamily is the second most important subfamily of liver CYPs in
metabolizing xenobiotics and endobiotics, and plays a critical role in metabolism of more
than 80 drugs in clinical use (Edeki , 1996) (Fig.1). CYP2D6 has been carefully studied
using recombinant techniques, but the same cannot be said for the nine different mouse
CYP2D members. Furthermore, differences in metabolism between CYP2D members
from human and mouse have not been thoroughly studied. A mouse knockdown model
would help determine CYP2D’s role in xenobiotic and endobiotic metabolism, and help
determine differences between the mouse and human CYPs. This important information
could be used to better assess human risk because mouse data are used to estimate the
adverse effects of drugs in humans.

CYP2A6 OTHER
CYP2B6

CYP1A2

CYP2D6 CYP2C9

CYP2E1

CYP2C19

CYP2C8

CYP3A4/5

Major CYP450 Content in Human Liver
CYP1A2
CYP2C19
CYP2C9/10
CYP2E1

CYP2D6
CYP3A4/5

Proportion of Pharmaceuticals Metabolized by Individual CYP450 Isoforms

Fig. 1: The role of CYP2D6 in drug metabolism: CYP2D6 is the second most important
liver CYP involved in drug metabolism.
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The CYP2D6 gene is highly polymorphic, and there are more than 90 known allelic
variants to date (http://www.imm.ki.se/CYPalleles/CYP2D6.htm). About 5 - 10% of
whites are poor metabolizers (Zanger et al., 2004), which might lead to individual
variation in response to many drugs. There are several reports indicating increased
disease risk and cancer association with genetic variation in CYP2D6. For example,
Parkinson’s disease (Kurth and Kurth, 1993), lung cancer, liver cancer, melanoma, and
breast cancer all show associations with CYP2D6 polymorphisms (Agundez, 2004).
CYP2D6 is responsible for metabolizing tamoxifen, a drug for breast cancer patients, to
its most active form, endoxifen. Patients with specific functional CYP2D6
polymorphisms who produce extremely low levels of active tamoxifen (poor metabolizer)
are at increased risk of breast cancer recurrence because of lack of tamoxifen efficacy
(Jin et al, 2005; Hartman and Helft, 2007).

Individuals with CYP2D6 polymorphisms may be poor metabolizers and predisposed to
drug toxicity caused by some drugs (e.g. antidepressants or neuroleptics). In contrast,
other drugs (e.g. codeine) may not be ineffective due to lack of activation. A classical
example of a chemical poorly metabolized by individuals with a CYP2D6 polymorphism
is debrisoquine (Mahgoub et al., 1977). Poor metabolizers have an increased hypotensive
response to the drug (Silas et al., 1977). Poor metabolizers may also be more likely to
develop plasma concentration related toxicity from impaired metabolism of phenytoin
(Idle et al., 1980), nortriptyline (Bertilsson et al., 1980) and perhexiline (Shah et al.,
1982).

6

An example of excessive metabolizers is the high expression of CYP2D6 in many
persons of Ethiopian and Saudi Arabian origin. CYP2D6 is not inducible, so these
excessive metabolizers have multiple copies of the gene probably to cope with the high
load of toxic alkaloids in their diet. These CYP2D6 enzymes therefore metabolize drugs
such as antidepressants and neuroleptics very quickly making them ineffective. On the
other hand, prodrugs will be extensively activated.

For example, codeine may be

metabolized into vast amounts of morphine.

The role of CYP2D6 and other CYPs in ADRs is critically important. It is estimated that
between 635,000 and 770,000 patients have a serious adverse drug reactions each year
and approximately 106,000 people die from ADRs in the United States (Lazarou, 1998).
Recent research suggests that pharmacogenetic data on P450 polymorphisms will
ultimately explain approximately 10-20% of ADRs. CYP2D6 is highly polymorphic,
because of that, it is very important for physicians to consider a person's race or genetic
background when drugs are given that may be metabolized differently by different
populations. If there is no other way to get rid of these drugs from the body, poor
metabolizers may be at life threatening risk.

Toxicology testing is performed on animals with drugs, pesticides, and other chemicals to
ensure the safety of people and the environment. However, the specificity of CYPs may
vary greatly between species (Higgins et al, 2003) and may vary with gender due to the
differing concentrations of sex hormones (David J. W. and Caitlin O, 2006).
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For

example, CYP2D9 is expressed only in male mice because of male-specific pulsatile
release of growth hormone (Kacew et al., 1995; Jarukamjorn et al 2006). Differences in
the expression and function of the CYP2D members between humans and rodents may
affect the outcome of toxicology studies (Baum and Strobel, 1997; Craig et al 2000).

A CYP2D6-humanized transgenic mouse model was previously developed to evaluate
and establish safe levels of chemical exposure and drug detoxification efficiency of
human CYP2D6. (Corchero et al, 2001; Yu et al, 2004). In this model, the transgene
includes the complete human wild-type CYP2D6 gene and its regulatory sequence and is
present in the mice at 5 + 1 copies per haploid genome (Corchero et al., 2001). Previous
studies showed that debrisoquine hydroxylase activity is enhanced in CYP2D6 transgenic
mice compared to wild-type mice indicating that CYP2D6 in humanized mice is
functional (Corchero et al., 2001). Moreover, this transgenic mouse line has been used to
establish that CYP2D6 is a 5-methoxyindolethylamine O-demethylase (Yu et al., 2003)
which means that this transgenic mouse line could be used as model to test CYP2D6
mediated metabolism. This model is believed to be a useful tool for investigating human
CYP2D6-mediated metabolism of xenobiotics, and endogenous compounds, extrahepatic
first pass metabolism by CYP2D6 and oral bioavailability of drugs. Also this model will
help us understand the role of CYP2D6-mediated metabolism in organ-specific toxicity,
pathologies, and disease. CYP2D6 expression was detected in liver, kidney, and intestine
of the transgenic mice (Corchero et al., 2001, Miksys et al, 2005).
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However, the humanized CYP2D6 transgenic mouse model still has the mouse CYPs
present; therefore, these CYPs can complicate the conclusions drawn from the data when
performing drug toxicity or metabolism studies. CYP2D knockout models are not
available because of difficulty in knocking out all nine mouse CYP2D isoforms. If one
could knockdown multiple CYP2D-isoforms instead using siRNA techniques that would
greatly enhance our ability to study the endogenous function of mouse CYP2Ds as well
as use these models to study human CYP2D6. However, prior to making a CYP2D
knockdown mouse, we must determine if the model will be useful and if it is feasible.
We aim to make an in vitro model system that reduces CYP2D RNA and protein
expression so that in the future we can better understand CYP2D’s role in drug
metabolism.

RNAi: (Fig.2). RNA interference (RNAi) techniques make use of a specific cellular
enzyme called Dicer that recognizes the double stranded RNA and chops it up into small
fragments between 21-25 bps in length. The short double-stranded RNA molecules of 2125 bps in length can target mRNA with complementary sequence for degradation via a
process termed RNAi. These short RNA fragments (called siRNA) for small interfering
RNA, bind to the RNA-induced silencing complex (RISC). The RISC is activated when
the siRNA unwinds and the activated complex binds to the corresponding complementary
mRNA using the antisense RNA. The RISC contains an enzyme to cleave the bound
mRNA and therefore causes suppression of gene expression. Once the mRNA has been
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cleaved, it can no longer be translated into functional protein.

(Fire et al , 1998;

Hammond et al 2000; Qiu et al 2005).

Dicer

siRNA
DUPLEX

RISK
activation

Target
mRNA
mRNA
degradation

No protein expression

Fig.2: RNAi: RNA interference works by forming a dsRNA that is processed by
Dicer, loaded onto RISC, and in turn forms a complex with specific
homologous mRNA that is targeted for destruction; thereby suppressing
translation.

In vitro studies showed that when short RNA duplexes are introduced into mammalian
cells in culture, sequence-specific inhibition of target mRNA expression can be achieved
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without triggering an interferon response. These short synthetic dsRNAs act catalytically
at sub-molar ratios and can cleave more than 95% of the target mRNA in the cell. In
dividing cells, the RNA interference effect can be long-lasting and may be detectable
after many cell divisions (Elbashir, S.M. et al. 2001, Caplen, N.J. et al 2001 and Sharp,
P.A. 2001). siRNA could be used to control the redundant function of CYP2D isoforms
and produce efficient knockdowns of CYP2D isoforms in vitro and in vivo.

This

technology is much less expensive than targeting specific genes in embryonic stem cells
to make knockouts as one or two constructs can be used to target multiple genes. Here,
we plan to use RNAi to knockdown the nine CYP2D subfamily members with a siRNA
homologous to CYP2D sequence. Ultimately, this could help us to study the exact
function(s) of mouse CYP2D’s in drug metabolism.

The main objectives of this study are to: a) Find and characterize an in vitro model
system (cell line) that expresses mouse Cyp2d enzymes; b) Design and test siRNA
constructs for their effectiveness at knocking down one or more murine Cyp2d isoforms;
and c) Compare differences in metabolite profiles between control and CYP2Dknockdown cells.
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INTRODUCTION

Cytochrome P450s (CYPs) are crucial endobiotic and xenobiotic phase I metabolism
enzymes.

CYPs are expressed in most organs and during embryogenesis, but the

majority of expression is within the liver (Abu-Abed et al., 2001; Otto et al., 2003;
Raunio et al, 1995), the body’s primary detoxification organ.

The constitutive

expression, inducibility, and activity of CYPs often explain differences in both the
therapeutic effects and toxicity of drugs (Nishimuta et al, 2011, Yuu et al, 2011).

In humans, the CYP2D subfamily has one functional isoform, CYP2D6 (Nelson et al.
1996).

Although CYP2D6 only constitutes about 2% of total hepatic CYP, it is

considered to be the second most important CYP involved in drug metabolism (Ingelman
et al, 2001). CYP2D6 is involved in the metabolism of over 80 drugs in clinical use,
including the selective serotonin reuptake inhibitors (SSRI), tricylic antidepressants,
betablockers, opiates, neuroleptics, and antiarrhythmics (Zhou SF, 2009). CYP2D6 is
highly polymorphic and there are more than 90 known allelic variants that cause
subsequent defect in drug metabolism (Sharon et al., 2005). Individuals who have two
homozygous copies for inactivating mutant CYP2D6 (i.e. both CYP2D6 alleles are nonfunctional), are called poor metabolizers (PM) and in turn the metabolism of many drugs
is slow in these individuals. PM are at risk of having a higher than expected serum
concentrations in relation to the drug dose, and at higher risk of side effects. On the other
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hand PM could have reduced effects when CYP2D6 metabolizes a “prodrug” into an
active metabolite. Examples include codeine and tamoxifen (Zanger et al., 2004).
Extensive metabolizers (EMs) have either one or two functional copies of the CYP2D6
gene. Some individuals are called ultrarapid metabolizers (UMs) because they may have
three or more active CYP2D6 alleles as a result of a hereditary gene duplication that
causes higher enzyme activity (Kirchheiner et al., 2008). UM often have low serum
concentrations and therefore receive less effect from the drug (Bradford LD, 2002,
Ingelman-Sundberg et al. 1999, Kirchheiner et al 2004).

In contrast to humans, mice have nine different mouse CYP2D genes; Cyp2d9, Cyp2d10,
Cyp2d11, Cyp2d12, Cyp2d13, Cyp2d22, Cyp2d26, Cyp2d34 and Cyp2d40 (Nelson et
al., 2004), most of them are expressed in livers (Sharon et al., 2005). There is limited
data on the expression and function of each of the isoforms, although Cyp2d22 has been
suggested to be the functional ortholog of human CYP2D6 (Blume et al., 2000 and Singh
et al 2009). Cyp2d9 is male specific and regulated by the STATs due to pulsatile growth
hormone release (Wong et al, 1987 and Park et al, 1999).

Proteomic studies

investigating CYP expression in the liver suggest that Cyp2d26 is expressed about
equally or slightly more than Cyp2d10, which is expressed at greater levels than Cyp2d9
(Sutton et al, 2010).

Although mice have been used to assess drug and toxicant metabolism, considerable
differences exist between the expression and catalytic activity of human and mouse
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CYP2D isoforms (Bogaards et al. 2000). For example, debrisoquine and bufuralol are
metabolized by human CYP2D6 but not by mouse CYP2Ds (Ai- and Robert, 2006; AlDabbagh et al., 1981; Kahn et al., 1985; Gonzalez et al., 1987; Masubuchi et al., 1997).

Limited information about mouse-specific metabolism, strain and gender differences can
cause problems in early drug development. Currently, a CYP2D6-humanized mouse
model can be employed to determine the biotransformation of therapeutics by CYP2D6
in vivo (Corchero et al., 2001; Yu et al., 2004), and it is assumed that the murine
CYP2Ds will not interfere because of their considerably catalytic differences. However,
there is the possibility that the murine CYP2D’s will confound data using the humanized
CYP2D6 mouse model. For example, CYP2D6 in human is a debrisoquine hydroxylase
while mouse Cyp2d9 was first characterized as a testosterone 16a-hydroxylase. No
common substrates have been reported for both CYP2D6 and Cyp2d9 enzymes (Gillian
et al., 1998). CYP2D6 substrates debrisoquine and bufuralol metabolized at a much
slower rate in mice. Moreover, Cyp2d22 metabolize codeine, dextromethorphan, and
methadone to codeine N-demethylation, dextromethorphan O-demethylation and
methadone N-demethylated respectively. While CYP2D6 metabolizes the same
substrates to codeine O-demethylation, dextromethorphan N-demethylation and
methadone is CYP2D6 inhibitor (Ai-M.Y and Robert L. H., 2006). Therefore, increased
knowledge of the metabolism of drugs by murine Cyp2d members can help reduce this
uncertainty.
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Because there are nine murine Cyp2d members, knocking them out by typical gene
targeting may not be practical, and is extremely expensive. Similarly, the role of Cyp2d
enzymes in mouse hepatocytes is difficult to determine without specific inhibition of all
of the Cyp2d members. One potential way to inhibit multiple Cyp2d isoforms is to use
RNAi. However, using RNAi to repress several CYPs in a subfamily has not been
previously done. Therefore, the purpose of this study was to test whether the expression
of multiple mouse Cyp2d isoforms could be repressed using single Cyp2d-siRNA
construct.
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MATERIALS AND METHODS

Cell Culture:
The mouse mammary tumor cell line, RIII/Pr1 was obtained from Strang Cancer
Research Laboratory (NY, USA). The mouse hepatoma cell line, HEPA1C1C7, was
purchased from ATCC (Manassas, VA, USA). CD-1 mouse primary hepatocytes were
purchased from either CellzDirect (Carlsbad, CA, USA) or Celsis in subsequent
experiments (Chicago, IL, USA). All cells were incubated at 37◦C and 5% CO2. The
immortal cell lines RIII/Pr1 and HEPA1C1C7 were maintained in DMEM (Dulbecco’s
Modified Eagle’s Media) with 1% penicillin/streptomycin , 10% fetal bovine serum, 1%
glutamine, 1% non-essential amino acids or Tropedo antibiotic mix from Celsis in
subsequent experiments. Mouse primary hepatocytes were obtained at approximately
750,000 cells / well in a 6-well plate and maintained in DMEM or Invitro GRO Hi
medium from Celsis for 24hrs before transfection.

siRNA design:
ClustalW was used to align the nine CYP2D subfamily members, and shRNAs were
designed against areas of high homology so that they would knockdown the expression of
all or at least multiple CYP2D isoforms (Fig. 5). In addition, two siRNA constructs
homologous to Cyp2d10 and a scrambled construct were designed by SABiosciences
(Frederick, MD, USA). The scrambled construct was used as a negative control for the
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down regulation of CYP2D expression. The sequence of each siRNA construct and
estimated knockdown efficiency is available in Table 2.

Table 2: DNA sequences of synthetically prepared siRNA constructs.
*siRNA Scales and predicted
efficiency

Cyp Family

siRNA Construct

Design A

TCCTGAGGTTCTTAATATGTT

18

Design B

CCAAGGTCAGAAGTCCTTACT

43

KD1

TCCAGAGATGGCAGACCAGGC

42

KD2

CCTCTTCTTCACCTGCCTCCT

42

*Predicted efficiency: Percentage of mRNA remaining in cells after siRNA directed
cleavage

Transfections:
Mouse primary cells were transfected according to the manufacturer’s protocol in eleven
6-well plates containing about 750,000 cells per well with siRNA using 2 µM,, 4 µM, 6
µM or 12 µM siRNA using SureFECT® (SABiosciences), TransIT-TKO® and TransITsiQUEST® (Mirus Bio, Madison, WI, USA) transfection reagents. The Label IT®
siRNA Tracker Kits® (Mirus Bio) was used to label scrambled siRNA and assess the
transfection efficiency of a siRNA construct. 8-well plate containing about 200,000 cells
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per well was transfected by the labeled siRNA and then was visualized 12hrs hour later
by confocal microscopy using a Zeiss LSM510 with optics for red and green
fluorescence. AxioVision and Carl Zeiss software were used to extract pictures and
compare fluorescence density in the transfected cells using FITC filter versus cells on
bright field to determine how many cells were transfected and level of florescence
between different transfection reagents. Transfection efficiency was determined by
dividing the number of cells shown at FITC filter by the number of cells shown at bright
field.

Sample Preparation:
When 90% confluent, mouse cell lines were collected while primary mouse hepatocytes
were collected after 24 hours. Cells were placed in Tri-Reagent® (Molecular Research
Center, Cincinnati, OH, USA) for RNA extraction or placed in microsomal buffer (80%
0.1 M phosphate buffer, pH 7.5, 20% glycerol) (Jill W., 2003) for Western blotting. All
samples were stored at -80C until RNA extraction followed by DNAse (Promega
Corporation, Madison WI) digestion to remove residual genomic DNA. RNA was
quantified spectrophotometrically at 260/280 nm and stored at –80oC. Reverse
transcription was performed to make cDNA using MMLV-RT, a dNTP mixture, and
random hexamers, and stored at –20oC.
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PCR:
Primers designing:
The updated list of the Cyp2d sequences was obtained from David Nelson’s Cytochrome
P450 homepage (http://drnelson.utmem.edu/CytochromeP450.html ). Gene-specific primer
pairs were designed with the assistance of the Primer3 program available at
http://wwwgenome. wi.mit.edu/cgi-bin/primer/primer3_www.cgi.

PCR was conducted in 50 µL reactions containing 2.5 U Taq polymerase, 2.5 µL 10x
buffer (Promega), 0.5 mm of each dNTP, 15 µM each gene-specific primer (Table 2) and
0.5 µL (1 ng/µL) of template cDNA. Amplicons were amplified using a AB Veriti 96
well PCR System thermocycler (Applied Biosystems inc.) using a protocol of 95 °C for 5
min, followed by 40 cycles of 95 °C for 30 sec, empirically determined annealing
temperature for 30 sec, 72 °C for 1 min, followed by a 10 min 70 °C final extension.
Amplification of each primer set was confirmed on a 1.5% agarose gel electrophoresis.
cDNA from male and female mouse livers were used as positive controls, and band sizes
were estimated using a 100-bp ladder (Qiagen).

Quantiative PCR
Quantitiave Real-time PCR (qPCR) was performed as described previously (Muller et al.,
2002; Hernandez et al., 2007; Hernandez et al., 2009b) using gene specific primers
(Table 3). PCR efficiency was determined from standard curves developed from 1:5 or
1:10 serial dilutions of a cDNA composite of all samples. Amplifications were performed
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in triplicate using a 96-well iQ5TM multicolor Real-Time PCR Detection System (BioRad, Hercules, CA,USA) with 0.25X SybrGreen (SaBiosciences/Qiagen, Frederick,
MD) to quantify gene expression. qPCR results were normalized to 18S rRNA
expression. A minimum of forty cycles were run on all real time samples to ensure a log
based growth curve. Quantification was done by taking the efficiency curve of the QPCR reaction to the power of the threshold cycle (Ct) over the housekeeping gene
(Muller et al., 2002). Statistical significance of the qPCR data was determined by t-tests,
or ANOVA followed by Tukey multiple comparison post-hoc test using GraphPad Prism
software (La Jolla, CA).
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Table 3: CYP2D primers used for PCR and qPCR.
Fragment Annealing Efficiency
size
temp.
%

Primers
F:GAGCAGAGGCGATTCTCTGT
Cyp2d9

400 bp

57.5◦C

NA a

101 bp

53.9◦C

90%

119bp

59◦C

113%

395 bp

61◦C

NA a

121 bp

51◦C

76%

100bp

59◦C

105%

R: CCCAGGTGGTCCTATTCTCA
F: TCCACTGAATTTGCCACGC
Cyp2d10
R:TCAGCACGGAGGACATGTTG
F: CCTTCATGGCCATACTGGAT
Cy2d11
R: ATTCCCCTTGGCCTTTTCTA
F: GGCGCTTCTCTGTGTCTACC
Cyp2d22
R: GTCCCAGGTCGTCTTGTGTT
F:TGCCTAAGGTTTCCTGTTGG
Cyp2d22
R:GTATCCCTGTTGGGTCATGG
F:TTCAAAAGCCTGGAAGCAGT
Cy2d26
R:TCCACCAGAAGCAGGAAGAT

Primer sequences were obtained from other sources or designed using the Primer3
program available at http://wwwgenome. wi.mit.edu/cgi-bin/primer/primer3_www.cgi.
a

Indicates a PCR primer and not used for qPCR
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Western blots:
Microsomes were isolated by differential centrifugation in the presence of aprotonin,
leupeptin, and PMSF as protease inhibitors. The S9-fraction was prepared by spinning
the cells with cytosol buffer at 10,000 rpm for 15 min, and the supernatant was collected.
Protein concentrations were quantified using commercially available reagents (Bio-Rad,
Hercules, CA) and stored at –80oC. Microsomal protein from wild-type mice was used as
a positive control. Western blots were conducted using 50-500 µg of microsomal protein
separated electrophoretically on a 10% polyacrylamide gel (SDS-PAGE), transferred to
nitrocellulose and incubated with a Rabbit anti-Human CYP2D6 polyclonal antibody
(Chemicon International, Billerica, MA, USA). The protein on the blots was detected by
chemiluminescence using Immun-Star AP Chemiluminescent Protein Detection Systems
(Bio-Rad Laboratories, Inc). The blots were scanned using Quantity One 4.6.5 1-D
analysis software (Bio-Rad Laboratories Inc,).

Testosterone hydroxylase assays
Testosterone hydroxylase assays were used to measure Cyp2d activity as previously
described (Hernandez et al., 2006). Mouse primary hepatocytes were transfected with 6
µM of scrambled and Cyp2d-KD1 siRNA. Twenty-four hours later, the cells were
exposed for 2 hrs to 50 uM [14C] testosterone (300,000 dpm/ml), extracted with ethyl
acetate, and testosterone metabolites were separated using thin-layer chromatography.
Metabolites were visualized by autoradiography, cut out, and quantified with a LS5801
liquid scintillation counter (Beckman, Fullerton, CA).

22

CYP2D6 Enzyme assay
6-well plate of primary mouse hepatocytes were transfected with 6 µM of scrambled or
Cyp2d-KD1 siRNA. 24 hrs later, the S9 fraction was isolated and stored at -80◦C.
P450-Glo™ CYP2D6 Assay kits (Promega, Madison, WI, USA) was used to compare
CYP2D activity between scrambled and Cyp2d-KD1 siRNA treated hepatocytes. The
procedures were done according to the manufacture protocol.

Tamoxifen Metabolism and HPLC
Twenty-four hours after siRNA transfection in 6-well plates with scrambled and Cyp2dKD1 constructs, the primary hepatocytes were treated with 500mM tamoxifen (SigmaAldrich, St. Louis, MO, USA). Cells and media were collected 2hrs later and stored at 80°C. Deconjugation was done by adding 20 units/ml of β-Glucuronidase (from bovine
liver) and Sulfatase (from Helix pomatia), and incubating for 2hr in a shaking water bath
at 37C. Extraction of the metabolites was done as described by (Kyung et al., 2003).
Internal standard of tamoxifen, 4-hydroxy-tamoxifen and endoxifen were made to
determine the extraction efficiency. Standard were filtered (0.22 µm PTFE filter; Fisher
Scientific, Pittsburgh, PA, USA) and metabolite concentrations were measured using
Reverse Phase-HPLC. Standards for all compounds were prepared in methanol and stored
at -20°C prior to analysis. Tamoxifen, 4-hydroxy-tamoxfen and endoxifen, were analyzed
using a Waters 1525 binary reverse phase-high phase liquid chromatography pump
(HyperSelect Gold C18, 5 µm, 120 Å particle size, 250 mm X 4.6 mm with guard
column; ES Industries Chromega Columns, West Berlin, NJ). The mobile phase consisted
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of 35% acetonitrile and 65% 20 mM potassium phosphate buffer (pH=3) over 70 minutes
at a flow rate of 1 ml/min. Chemical detection was determined at excitation wavelength
of 256 nm and an emission wavelength of 380nm. The detection limit for 4-hydroxytamoxifen and endoxifen were 0.005 and 0.0025 mg/ml, respectively.
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RESULTS AND DISCUSSION

Expression of Cyp2d isoforms in cell culture
Two different immortal murine cell lines and primary mouse hepatocytes were used to
assess Cyp2d isoforms expression. The mouse hepatoma cell line, HEPA1C1C7, did not
express any of the Cyp2d isoforms tested by Western blotting or PCR. The murine
mammary tumor derived cell line, RIIIPrI, expresses Cyp2d22 but no other Cyp2d
members were detected (Fig.3, b). Protein expression was not detected by Western
blotting (Fig.3, a). Therefore, we determined that murine immortal cell lines did not
contain enough CYP2D for subsequent knockdown by siRNA.
Mouse primary hepatocytes from male CD-1 mice showed expression of Cyp2ds as
demonstrated by western blotting analysis (Fig.4b).

Furthermore, PCR analysis

demonstrated that Cyp2d10, Cyp2d11, Cyp2d22 and Cyp2d26 are expressed in mouse
hepatocytes (Fig. 4a). However, Cyp2d9, a male specific CYP, was not expressed in the
male primary hepatocytes. cDNA from the livers of wild-type male (WT-M) mice
expressed Cyp2d9, but wild-type female (WT-F) did not show expression of this CYP.
Cyp2d9 expression is controlled by the release of growth hormone in a pulsatile fashion
(Gianpaolo and Walter, 2011). Therefore, we hypothesized that the loss of pulsatile
growth hormone release from the anterior pituitary in cultured cells caused the loss of
Cyp2d9 expression from the male primary hepatocytes within 48 hours. This suggests
that male sexual dimorphism mediated by growth hormone is difficult to sustain in
culture.
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Fig. 3: CYP2Ds expression in murine cell lines. (A) Protein expression of CYP2Ds in
mouse hepatoma cell line HEPA1C1C7 and RIIIPrI by Western blotting with
500 µg protein. Microsomes from wild-type male mouse livers (WT-M) were
used as positive controls. (B) PCR detection of Cyp2ds in the HEPA1C1C7
and RΙΙΙPrΙ cell lines.
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Fig. 4: Detection of murine CYP2D isoforms in mouse primary hepatocytes. (A) PCR
detection of Cyp2d9, Cyp2d10, Cyp2d11, Cy2d22 and Cy2d26 in primary
hepatocytes. Hep = primary hepatocytes; WT = wild-type; M = male; F = female.
(B) Western blot using polyclonal antibody for CYP2D in mouse primary
hepatocytes compared to microsomes from WT-M mouse livers.
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CYP2D similarity and siRNA design
There are nine CYP2D isoforms in mouse, and some probably have redundant functions.
Multiple Sequence Alignments (ClustalW) indicate that there are two areas of the
CYP2D isoforms that are highly homologous, and therefore it was possible that one
siRNA could knockdown the expression of all nine isoforms (Fig. 5). We designed
siRNA to target all nine isoforms based on these alignments and called them Cyp2d-KD1
and Cyp2d-KD2. Cyp2d-KD1 is expected to repress the expression of all of the Cyp2d
isoforms, while Cyp2d-KD2 is expected to target all but cyp2d10 because of a single
nucleotide mismatch in the middle of the sequence. To evaluate and compare our siRNA
designs to siRNAs specific to only one gene; two siRNAs designed to target Cyp2d10
were purchased from SABiosciences, and named Cyp2d10-desgin A and Cyp2d10-design
B (Table 3). siRNA scales (http://gesteland.genetics.utah.edu/siRNA_scales/) was used to
estimate the level of Cyp2d expression following transfection with each siRNA construct
(Mateeva et al 2007) (Table 3).
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Cyp
Family

Cluster sequences of Mus musculus Cyp2ds mRNA

Cyp2d-KD1

Cyp2d9
Cyp2d12
Cyp2d10
Cyp2d11
Cyp2d34
Cyp2d26
Cyp2d22
Cyp2d13
Cyp2d40

Cyp2d-KD2

Cyp2d9
Cyp2d12
Cyp2d10
Cyp2d11
Cyp2d34
Cyp2d26
Cyp2d22
Cyp2d13
Cyp2d40

Cyp2d10Design A

Cyp2d10Design B

Cyp2d9
Cyp2d12
Cyp2d10
Cyp2d11
Cyp2d34
Cyp2d26
Cyp2d22
Cyp2d13
Cyp2d40

Cyp2d9
Cyp2d12
Cyp2d10
Cyp2d11
Cyp2d34
Cyp2d26
Cyp2d22
Cyp2d13
Cyp2d40

TCATAGGGCAGGTGAGGCATCCAGAGATGGCAGACCAGGCCCACATGCCC
TCATAGGGCAGGTGAGGCATCCAGAGATGGCAGACCAGGCCCACATGCCC
TCATAGGGCAGGTGCGGCATCCAGAGATGGCAGACCAGGCTCGTATGCCC
TCATAGGGCAAGTGCAGCATCCAGAGATGGCAGACCAGGCTCGCATGCCC
TCATAGGGCAGGTGCGGTGTCCAGAGATGGCAGACCAGGCCCGCATGCCC
TCATAGGGCACGTGCGGCATCCAGAGATGGCAGACCAGGCCCGCATGCCC
TCATAGGGCAGGTGCAGTGTCCAGAGATGGCAGACCAGGCTCGCATGCCC
TCATAGGGCAGGTGCGGTGTCCAGAGATGGCAGACCAGGCCCACATGCCC
TCATAGGGCAGGCACGGCGTCCAGAGATGGCAGACCAGGCCCGCATGCCC

CCTCTTCTTCACCTGCCTCCTGCAGCGCTTTAGCTTCTCAGTGCCTGATG
CCTCTTCTTCACCTGCCTCCTGCAGCGCTTTAGCTTCTCAGTGCCTGATG
CCTCTTCTTCACGTGCCTCCTGCAGCACTTTAGCTTCTCAGTGCCCAATG
CCTCTTCTTCACCTGCCTCCTGCAGCGCTTTAGCATCTCAGTGCCTGATG
CCTCTTCTTCACCTGCCTCCTGCAGCGCTTTAGCTTCTCAGTGCCAGCTG
CCTCTTCTTCACCTGCCTCCTGCAGCGCTTTAGCTTCTCAGTGCCCGATG
CCTCTTCTTCACCTGCCTCCTGCAGCGCTTTAGCATCTCAGTGCCCGATG
CCTCTTCTTCACCTGCCTCCTGCAGCGCTTTAGCTTCTTAGTGCCTGCTG
CCTCTTCTTCACCTGCCTCCTGCAGCGCTTTAGCTTCTCAGTACCGGATG

TCCTGAGGTTCTTAATGCATTCCCGATACTCTTGCGTATCCCAAGGCTGGCTG
TCCTGAGGTTATTAACACATTCCCGATACTCCTGCACATCCCAAGGCTGGCTG
TCCTGAGGTTCTTAATATGTTCCCCATACTCCTGCGCATCCCAGGACTGCCTG
TCCTGGGGTACTTAATGAGTTCCCAATATTCCTGCGCATCCCAGGGCTGGCTG
TCCTGGGGTTCTTAACACGTTCCCAATACTCCTGCGAATCCCAGGGCTGGCTG
CGGAGAGGTGCTGAATGCCATCCCAATGCTACTACACATCCCTGGTTTGCCTG
ACCCATGTTCCTGAATGTGTTCCCGATGCTCCTGCGCATCCCGGGGCTGGTTG
TCCAGAGGTTCTGAACACATTTCCAATTCTCCTGCACATCCCAGGGTTGGCTG
TTACAAGGTTGTGAAGATGTTCCCAATTGTCCTGCGCATCCCAGGGTTGGCTG

ACAAGGCCCTCCAAGGTCAGAAGTCCTTCATCGCCATACTGGATAACCTG
ACAAGTTCCTGCAAAGTCAGAAGTCCTTCATCGCCATAGTGGATAACCTG
GGAAGGTCTTCCAAGGTCAGAAGTCCTTACTGGCCATAGTGGAGAATCTG
ACATGGTCTTCCAAGGTCAGAAGTCCTTCATGGCCATACTGGATAACCTG
ACATGGTCTTCCAAAGTCAGAAGACCTTCATGGCCATACTGGATAACCTA
ATAAAGCCTTCCCCAAGCTGAATTCATTCATAGCCTTAGTGAATAAGATG
GCAAGGTCTTCCCTGGGAAAAGGGCCTTTGTTACCATGTTGGATGAGCTG
ACAAAGTCTTCCCTGGGCAAAAGACATTTCTCACCCTGGTAAATAAGCTG
ATAAAATCTTCCCTGGGCAAAAGACATTTCTCACCATGGTGGATAAGCTG
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Fig.5: Target areas of each of the siRNAs. Homologous areas of each of the CYP2D
isoforms to each of the siRNAs were determined by CLUSTALW. CYP2D-KD1
and CYP2D-KD2 were purposely designed to target multiple CYP2D isoforms.
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Knockdown of Cyp2d isoforms by siRNA:
In our first trial, primary hepatocytes were transfected with 2 µM or 6 µM of siRNA for
each the siRNAs (including a scrambled construct) using SureFECT transfection reagent.
qPCR was used to evaluate the expression of Cyp2d10, Cyp2d11, Cyp2d22 and
Cyp2d26. Cyp2d10 expression was significantly down regulated by siRNA with
Cyp2d10-design A and Cyp2d-KD1 at both 2 µM and 6 µM in a dose dependant manner.
Cyp2d10-design B only reduced Cyp2d10 expression at 6 µM. The percent knockdown
ranged from 10-50% for each of these siRNAs (Fig. 6). In contrast, Cyp2d10 was upregulated when Cyp2d-KD2 was transfected into hepatocytes at 2 µM and 6 µM (Fig. 6).
Cyp2d-KD2 was designed to knockdown the expression of all of the CYP2D members
except Cyp2d10, indicating that the loss of the other Cyp2d members may have caused a
compensatory reaction that led to an increase in Cyp2d10 expression. Currently, the
transcription factors that regulate Cyp2d10’s inducibility are not known and it has been
suggested that most Cyp2d isoforms are not inducible (Tomohiro et al., 2000); however,
this data appears to indicate that Cyp2d10 is inducible. Overall, with the exception of
Cyp2d-KD2, all of the designs were able to knockdown Cyp2d10 expression at about the
same range, but none repressed expression greater than 50%.

Cyp2d11 mRNA expression was not significantly repressed by any of the siRNA designs;
however, trends suggest that all of the constructs showed some ability to reduce Cyp2d11
expression about 50% with Cyp2d-KD1 showing the greatest potency (Fig. 7).
Similarly, the expression of CYP2D22 (Fig. 8) and Cyp2d26 (Fig. 9) were not
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significantly repressed by any of the siRNA constructs. However, two trends were
observed. The siRNA constructs designed to repress the expression of all of the Cyp2d’s
were more efficacious than those designed to only repress the expression of Cyp2d10.
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Fig. 6: Relative expression of CYP2D10 in mouse primary hepatocytes that were
transfected with 2µM and 6µM siRNA design A (A), design B (B), KD1 (C), and
KD2 (D) compared to hepatocytes transfected with scrambled siRNA. An
asterisk indicates statistical significance (p < 0.05) by ANOVA followed by
Tukey multiple comparison post-hoc test (n = 3).
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Fig.7: Relative expression of CYP2D11 in mouse primary hepatocytes that were
transfected with 2µM and 6µM siRNA design A (A), design B (B), KD1 (C), and
KD2 (D) compared to hepatocytes transfected with scrambled siRNA. No
significant differences (p < 0.05) were detected by ANOVA followed Tukey
multiple comparison post-hoc test (n = 3).
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Fig. 8: Relative expression of CYP2D22 in mouse primary hepatocytes that were
transfected with 2µM and 6µM siRNA design A (A), design B (B), KD1 (C), and
KD2 (D) compared to hepatocytes transfected with scrambled siRNA. No
significant differences (p < 0.05) were detected by ANOVA followed by compared
to scrambled post-hoc test (n = 3).
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Fig.9: Relative expression of CYP2D26 in mouse primary hepatocytes that were
transfected with 6µM siRNA design A (A), design B (B), KD1 (C), and KD2 (D)
compared to hepatocytes transfected with scrambled siRNA. No significant
differences (p < 0.05) were detected by Student’s t-test (n = 3).
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The data indicates that Cy2d-KD1 and Cyp2d-KD2 were able to show some loss of the
expression of multiple CYP2Ds in the primary hepatocytes as planned; however, the
expression loss was often not significant and weaker than anticipated. Cyp2d-KD2 also
caused an increase in the expression of Cyp2d10 probably because of a compensatory
reaction, and therefore this siRNA construct is not useful for knocking down the
expression of all hepatic CYP2D members. Interestingly, the two designs for Cyp2d10
worked specifically based on statistically analysis; however, subjectively there appears to
be a consistent down-regulation of other isoforms such as Cyp2d11 and Cyp2d22. Given
the high homology between the Cyp2d10 and Cyp2d11 this was expected.

Based on these results, we determined that the best overall siRNA construct for
repressing multiple Cyp2d isoforms was Cyp2d-KD1.

However, expression was not

repressed as much as desired. These results suggested that optimizing the transfection by
increasing the siRNA dose or using multiple siRNA might be necessary to obtain higher
knockdown efficiency.

Subsequently, primary hepatocytes were transfected with a higher concentration of
Cyp2d-KD1 siRNA (12 µM), and with a mix of Cyp2d10-design A, Cyp2d-KD1 and
Cyp2d-KD2 in order to achieve greater repression of CYP2D expression. However,
knockdown efficiency was dramatically decreased with higher concentrations of siRNA
suggesting that multiple siRNA could be competing for processing by Dicer/RISC and
inhibiting the deactivation initiated by Cyp2d-KD1. However, we consider it a more
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likely alternative that 12 µM of siRNA was too great for the cells and elicited toxicity or
maybe an interferon response (Scott et al., 2007) leading to down-regulation of many
genes in the cells transfected with scrambled or Cyp2d-targeted siRNAs, and an inability
to accurately quantify Cyp2d isoforms.

Transfection efficiencies and toxicity:
Based on our marginal first set of results with 2 µM and 6 µM siRNA and our poor
results with 12 µM siRNA, we hypothesized that poor transfection efficiency in primary
hepatocytes is the problem and we should try different transfection reagents. Our first set
of siRNA transfection produced marginal to poor results with great variability, potentially
because of poor transfection efficiency in the primary mouse hepatocytes. Therefore, we
compared transfection efficiency between three different transfection reagents:

The

reagents we tried were SureFECT, the first transfection reagent we used but one
optimized for immortal cells, and TransIT-TKO and TransIT-siQUEST produced for use
with primary cell culture.

Primary mouse hepatocytes were transfected with fluorescence labeled scrambled siRNA
and transfection efficiency examined based on the number of cells transfected
(fluorescence using FITC filter) divided by the total number of cells (in Bright light
field). Nearly 100% transfection efficiency was achieved by using TransIT-siQUEST
transfection reagent (Fig. 10). Lower transfection efficiencies were observed following
transfection with TransIT-TKO and SureFECT, both appeared 90% effciency (Fig. 10).
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However, cellular debris consistent with cellular toxicity was observed in the cells
transfected with TransIT-siQUEST and SureFECT but not TransIT-TKO (Fig. 10).

Fig. 10: Comparison of the transfection efficiency of three different transfection reagents
in primary mouse hepatocytes; TransIT-TKO and TransIT-siQUEST from Mirus
Bio and SureFECT from SABiosciences were used to transfect cells with
fluorescence labeled siRNA probes and visualized using confocal microscopy
(40 x objective).. TransIT-seQUEST had the best transfection efficiency, but this
reagent also caused significant toxicity and repression of CYP2D isoforms was
not observed. TransIT-TKO had reasonable transfection efficiency with little
toxicity, while SureFECT appeared to work well, but the relatively high
efficiency led to high toxicity.

Primary hepatocytes were transfected with 6 µM siRNA and either Cyp2d-KD1 or
scrambled siRNA using TransIT-siQUEST transfection reagent because of its high
transfection efficiency. However, upon collecting the cells 24 hours after transfection,
most of the cells were poorly attached to the plate and appeared dead. RNA extracted
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from the cells was of poor quality and the level of Cyp2d10 expression did not vary
between scrambled and Cyp2d-KD1 treated hepatocytes.

TransIT-TKO transfection reagent was the only reagent that did not cause an increase in
cellular debris, and therefore subsequent studies were performed with this transfection
reagent. The first set of transfections performed with TransIT-TKO were done to serve
the dual purpose of testing whether this transfection reagent worked well, and to test
whether the scrambled siRNA construct interfered with Cyp2ds expression. A 6-well
plate of primary hepatocytes were mock transfected, transfected with 6µM of scrambled
siRNA, or transfected with Cyp2d-KD1 using TransIT-TKO transfection reagent (n = 2).
The mRNA expression of Cyp2d10, Cyp2d11, Cyp2d22 and Cyp2d26 did not vary
between mock transfected and scramble-transfected hepatocytes indicating that the
scrambled siRNA has no adverse interfering actions on the cells. In comparison, Cyp2dKD1 significantly repressed the expression of Cyp2d11 and Cyp2d22, and if not for the
high variability of Cyp2d10 expression in the mock transfected cells Cyp2d10 would
have been significantly repressed (Fig.11). Overall, Cyp2d-KD1 in conjunction with
TransIT-TKO showed an improved knockdown efficiency of 50-70%. Large variability
of CYP2D expression was observed in the wild type primary hepatocytes indicating that
CYP2D polymorphism could be exist in mice. Further studies are still required to test the
polymorphism in mouse Cyp2ds. Different in-breds and batched samples from different
places would be the best way to check the reason behind the variability of enzymes
activity.

38

B
Relative Expression

Relative Expression

A

1.2

1.2

0.8

0.8

0.4

*

0.4

0.0
UT

SC

0.0

KD-1

UT

SC

KD-1

Cyp2d11

Cyp2d10

C

D

Relative Expression

Relative Expression

1.2
1.2

0.8

0.8

*

0.4

0.4

0.0

0.0
UT

SC

UT

KD-1

SC

KD-1

Cyp2d26

Cyp2d22

Fig. 11: Relative expression of CYP2D in untreated (UT), scrambled (SC) and KD1
treated primary mouse hepatocytes. UT are cells that were mock-transfected, SC
are cells that were transfected with the scrambled siRNA construct, and KD-1
are cells that were transfected with the KD-1 siRNA construct. An asterisk
indicates statistical significance (p < 0.05) by ANOVA followed by Tukey
multiple comparison post-hoc test (n = 2).
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Primary mouse hepatocytes were used in metabolism study as an in vitro model system
for detecting metabolites difference between wild type and knockdown. To make sure
this work is repeatable and to ensure knockdown occurs during the metabolism assays,
four 6-well plates of mouse primary hepatocytes were transfected with 6 µM of Cyp2dKD1 and scrambled siRNA using the TransIT-TKO transfection reagent. One plate used
for RNA extraction and qPCR, while the other three plates used for detecting CYP2D
activity in metabolizing three different substrates. qPCR results showed that Cyp2d-KD1
was able to significantly knockdown the expression of all the hepatic Cyp2d isoforms
tested, Cyp2d10, Cyp2d11, Cyp2d22 and Cyp2d26, at 6 µM with a knockdown
efficiency of 50-70% (Fig. 12). Overall, an improvement over the first set of experiments
in both efficiency of knockdown and the number of genes significantly repressed was
observed. This demonstrates that of the three transfection reagents used TransIT-TKO is
the best based on lower toxicity coupled with reasonable transfection efficiencies.
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Fig.12: Repression of CYP2D expression in primary hepatocytes is repeatable using the
TransIT-TKO transfection reagent and the KD1 construct. An asterisk indicates
statistical significance (p < 0.05) by Student’s t-test (n = 3).
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Testosterone hydroxylation assay
Cyp2d-mediated changes in testosterone metabolism were investigated after transfection
with the scrambled and Cyp2d-KD1 constructs. Mouse Cyp2ds have sterio- and regiospecifically hydroxylate testosterone at the 16α-position (Baldwin and LeBlanc, 1992).
The data showed no significant difference in 16α-hydroxylation between scrambled and
Cyp2d-KD1 siRNA treated cells (Fig. 13). There are several potential explanations for
the Cyp2d-KD1 construct to not reduce 16α-hydroxylation. For example, while Cyp2d
mRNA levels are lower after 24- hours, a significant RNAi-mediated drop in protein
levels may take 48-72 hours (Mike Byrom, 2004; Francesco et al., 2006).

Cyp2d9,

which is a male specific isoform responsible for testosterone metabolism, was not
expressed in detectable level in vitro, and therefore Cyp2d’s role in 16a-hydroxylation
may have been minimized. This in turn could have caused allowed for other CYPs such
as the Cyp2b’s or Cyp2c’s to play a primary role in 16α-hydroxylation of testosterone in
vitro. Lastly, the expression of most CYPs in primary hepatocytes drops precipitously
during monolayer culture; however, Cyp2b9 expression does not drop and Cyp2b10
expression increases 15X (Karen M. et al., 2009). Therefore, these Cyps may have
performed most of the 16a-hydroxylation and in turn the effects of Cyp2d-KD1 on Cyp2d
activity were concealed.
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KD1

SC

Control

16a-hydroxytestosterone

Fig. 13: Autoradiograph of [14C] hydroxytestosterone metabolites following thin layer
chromatography (TLC)

P450-Glo(tm) enzyme assay
Luminogenic CYP2D6 substrate was incubated in S9 fractions from primary hepatocytes
from Cyp2ds enzyme activity was tested in S9 fractions prepared from scrambled and
Cyp2d-KD1 treated primary hepatocytes by incubating luminogenic CYP2D6 substrate.
The results showed no significant difference was observed in the Cyp2ds activity
between scrambled and Cyp2d-KD1 siRNA transfected cells (Fig. 14). This enzyme
assay was designed for CYP2D6 activity which could not be the same for mouse
CYP2Ds. Excessive esterase activity in cell model would interfere with the substrate
stability. This could explain the low level of enzyme activity in the tested cells.
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Fig. 14: P450-Glo(tm) enzyme assay: Cyp2d enzyme activity from the S9 fraction of
scrambled- (SC; control) and Cyp2d-KD1 (KD1) - treated primary hepatocytes
when incubated with luminogenic CYP2D6 substrate.

Tamoxifen metabolism
Tamoxifen is in part metabolized by CYP2D6 (Vincent et al., 2008) (Fig. 15).
Tamoxifen is metabolized to 4-hydroxytamoxifen by CYP2D6 as well as other CYPs,
and in turn can be metabolized by CYP3A4 to Endoxifen. Tamoxifen is also metabolized
by CYP3A4 as well as other CYPs to N-desmethyltamoxifen (NDM-tamoxifen), and in
turn metabolized primarily by CYP2D6 to endoxifen.
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Fig. 15: Tamoxifen metabolism by CYPs. Tamoxifen is metabolized by several
CYPs. The metabolism of NDM
NDM-tamoxifen
tamoxifen to Endoxifen is primarily
performed by CYP2D6 in humans.

After RNAi incubation, the metabolites of tamoxifen were measured by HPLC to test
whether Cyp2d-KD1
KD1 perturbed Cyp2d
Cyp2d-mediated metabolism off tamoxifen. The 44
hydroxytamoxifen standard elutes at 34 minutes; hhowever, we primarily observed a
metabolite that eluted at 37--39 minutes. NDM tamoxifen was not observed and was of
little interest because it is not produced by CYP2Ds. Endoxifen was clearly the dominant
metabolite measured by HPLC as approximately 30X more endoxifen was detected than
the other metabolites. Endox
Endoxifen
ifen is the ultimate phase I metabolite produced during this
reaction.

The data showed that there is no significant difference in tamoxifen metabolism between
scrambled and Cyp2d-KD1
KD1 siRNA treated hepatocytes (Fig. 16). The ability of the
knockdown model to metabolize the tamoxifen as efficient as wild type cells could be
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explained by the possibility of other mouse CYPs in metabolizing the substrate. Another
possibility is that the ideal knockdown efficiency was not achieved yet so the remaining
CYP2D protein that is still expressed is able to metabolize the drug.

Endoxifen
200

ug/ml Endoxifen

175
150
125
100
75
50
25
0
SC

KD1

Treatment
Fig. 16: Tamoxifen metabolism was not perturbed by Cyp2d-KD1 siRNA. Endoxifen
was the primary metabolite detected.

In summary, one siRNA construct can be used to repress the expression of number of
homologous Cyp subfamily members. However, repressing the expression of several
Cyps may have unexpected consequences for the expression of other Cyps that were not
targeted by the siRNA as Cyp2d10 expression was significantly increased following the
knockdown of other CYP2D members. Transfection of primary mouse hepatocytes with
6uM of Cyp2d-KD1 and TransIT-TKO was successfully able to knockdown the
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expression of multiple Cyp2ds, however, the knockdown cells were still able to
metabolized the selected compounds. We hypothesize that more time is necessary for the
loss of Cyp2d isoforms, and for proper loss of protein expression we would need to
incubate the cells in the siRNA for 48 hours or more. Because primary hepatocytes
continually lose the expression of most CYPs including Cyp2d isoforms (Karen M. et al.,
2009), this may preclude the use of siRNAs to functionally knockdown Cyp2d expression
in monolayer primary hepatocyte cultures.
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CONCLUSIONS

Multiple Cyp2ds isoforms (Cyp2d10, Cyp2d11, Cyp2d22 and Cyp2d26) were expressed
in detectable level in mouse primary hepatocytes, and this made it a possible in vitro
model system to study Cyp2ds function(s). Knockdown the expression of multiple
Cyp2ds was the main objective of this study by using a single construct of siRNA
(preferentially Cyp2d-KD1). Optimizing the transfection condition for the highest
knockdown efficiency was achieved by using siRNA at concentration of 6µM and
TransIT-TKO transfection reagent. Scrambled treated hepatocytes did not have any
effect on Cyp2d expression and therefore comparing the level of expression of Cyp2dKD1 treated hepatocytes to that of scrambled treated hepatocytes was a valid comparison.
Since hepatocytes represent the most appropriate model for the evaluation of integrated
drug metabolism that contributes to estimate human specific toxicity, this knockdown
model was used to test for metabolizing efficacy of known CYP2D6 substrates.
However, the loss of CYP2D activity overtime in vitro and/or species differences in
enzyme activity may explain the failure of the knowdown model to show any differences
in the metabolite profile or quantification after incubation of tamoxifen, testosterone, or
the luminogenic CYP2D6 substrate compared to controls cells. The overall objectives
from this work are to identify a simple method to manipulate an in vitro model,
knockdown the expression of multiple CYP2D and conduct functional drug metabolism
studies.
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In the liver, drug metabolism is a multistep process starting with phase I reactions
(oxidation, reduction, and hydrolysis) then phase II reaction (conjugation). Therefore, the
liver is the critical organ when studying the drug pharmacokinetics. CYP2D is a crucial
set of phase I enzymes and plays a central role in the metabolism of many xenobiotic and
endogenous compounds (Nelson et al., 1996). Moreover, several drug-metabolizing
enzymes including CYP2D6 have been shown to be polymorphic (Ingelman-Sundberg,
2002; Miners et al., 2002) indicating that genetic polymorphism can cause differences in
the drug pharmacokinetics. Induction and inhibition of drug metabolizing enzymes are
causes of drug interaction. Serious drug interactions involving P450 have been reported
(Dresser et al., 2000; Niemi et al., 2003). For example, Terfenadine and cisapride were
withdrawn from the market because of the QT prolongation caused by the inhibition of
CYP3A4 by a coadministered drug (e.g. triazole antifungal agent). Prediction of adverse
drug reactions (ADR) is critical in drug development.

In the preclinical stage, human-derived sources or experimental animals are common
models to perform the pharmacokinetics. Human liver microsomes and human
hepatocytes in primary culture are used nowadays as tools during drug development.
Human liver microsomes have an advantage; microsomes can be stored for a few years
without the loss of enzyme activities but the problem is it cannot be used to evaluate any
induction potencies. Human primary hepatocytes express all the drug metabolizing
enzymes, but the there is a huge loses of enzyme activity overtime and the availability of
donor material is limited and their large variability between donors (Schaeffner et al.,
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2005; Gomez-Lechon et al., 2003; Rodrigues and Rushmore, 2002). Because of
disadvantages and limitations of using human models, experimental animals, in vitro
animal models and humanized transgenic lines are the most widely used models to
perform the pharmacokinetics studies recently. An in vitro mouse hepatocyte system
might be an alternative to the human systems, especially if the metabolic competence is
preserved (Jae et al, 2011). Since the complete sequence of the mouse genome is
published (Waterston et al., 2002) and chimeric mouse models are widely used, primary
mouse hepatocytes are usable for the purpose of performing drug metabolism studies
(Karen et al 2009). Furthermore, rodent systems have been used for years so there is
historic data that can be used to estimate whether particular metabolite pathways are
relevant to human health.

In this study, two mouse cell lines (HEPA1C1C7 and RΙΙΙPrΙ) and mouse primary
hepatocytes were characterized for expression of mouse CYP2Ds. Cyp2d22 is the only
isoform detected in RΙΙΙPrΙ cell line. HEPA1C1C7 did not show any expression of the
nine CYP2D isoforms. Mouse primary hepatocytes showed expression of Cyp2d10,
Cyp2d11, Cyp2d22 and Cyp2d26 using specific primers for PCR and real time PCR.
Also western blot analysis showed detectable level of Cyp2d protein in the primary
culture when Cyp2d specific polyclonal antibody was used. This makes primary culture
to be the in vitro model system of choice and the one we used in studying Cyp2d
expression function(s) and their role in metabolizing xenobiotics and endobiotics
compounds. However, primary culture has a short duration of survival and every step
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towards a more gentle handling and transfection are critical to maintain cell vitality.
Another drawback of primary culture is the huge lose of enzyme activity in a timedependent manner (Kienhuis et al., 2007; Karen M. et al. 2009) and information about
stability of liver specific functions in mice is scarce (Karen et al, 2009). In conclusion,
primary hepatocytes have advantages of expressing CYP2D; however, this in vitro model
has some limitations.

In mouse there are at least nine isoforms of CYP2Ds (Nelson et al., 2004). Those
isoforms have great sequence similarities and there is a belief of having redundant
interfering functions. This interfering function could make the humanized mouse model
less useful for studying the function of CYP2D6 in polymorphic individuals. Knocking
out those nine isoforms is expensive and may not be a practical approach while knockingdown CYP2Ds could be done to study the function of mouse CYP2Ds and eliminate their
redundant interfering function in the humanized mouse model. The discovery of small
interference RNA has provided novel avenues to enhance gene function studies as well as
drug target discovery (Romano et al., 1992; Tang et al., 2003).

Using a single construct of siRNA to knockdown the expression of multiple Cy2ds was
the main objective in this study. After looking at the highest sequence similarity between
the CYP2D nine isoforms, two siRNA constructs were designed in this study (Cyp2dKD1 and Cyp2d-KD2) to knockdown multiple CYP2Ds at once. The results showed that
Cyp2d-KD1 was successfully able to knockdown multiple CYP2Ds. On the other hand
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Cyp2d-KD2 induces Cyp2d10 expression, presumably as a compensatory mechanism to
overcome the down regulation of the other isoforms.

The transcriptional regulation of CYP2D in mice remains unknown. In terms of gene
regulation of CYP2D, several liver-enriched transcription factors and expressed factors
are responsible for the constitutive expression of the CYP2D subfamily in humans and
rodents (Lee et al., 1994; Yokomori et al., 1995a, b; Cairns et al., 1996; Mizuno et al.,
2003). Previous studies showed that HNF4α controls constitutive levels of expression of
the CYP2D6 gene. Moreover, CYP2D6 gene expression was down-regulated by the
depletion of HNF4 α using adenovirus- mediated antisense targeting that selectively
diminishes HNF4 α content in human hepatocytes, (Javier et al., 2001; Jover et al.,
2001). This indicates that further studies may be still needed to explain the compensatory
induction of Cyp2d10 in the Cyp2d-KD2 knockdown model.

Our data indicates that Cyp2d-KD1 is the siRNA of choice to knockdown multiple
CYP2Ds at once. Also, using siRNA at a concentration of 6µM was the best tolerated
dose without triggering an interferon response or significant cell toxicity. Interferon
(IFN) activation and induction of the cellular dsRNA-dependent protein kinase (PKR)
response in mammalian cells can be a possible drawback of the use of higher dose of
RNAi, which in turn inhibits all protein expression. Therefore, siRNAs were designed to
be <~30 bp to avoid the PKR response and avoid nonspecific effects on gene silencing
(Caplen et al. 2001; Elbashir et al. 2001). While using lower siRNA concentration (2µM)
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was not able to effectively repress multiple CYP2Ds; higher concentration of siRNA (12
µM) and using combination of multiple siRNA caused obvious cell toxicity and
inconsistent cellular response in the transfected hepatocytes.

Primary mouse hepatocytes were shipped to us 24hrs after isolation. The cells had a 90%
confluence, displayed a classical polygonal shape and demonstrate a successful
monolayer adhesion in the coated collagen surface of the 6-well plate. When TransITsiQUEST transfection reagent, or multiple siRNA, or higher siRNA dose (12µM) was
used, cell debris was observed, the cells looked dead, and the RNA extracted was of poor
quality. Optimizing the transfection efficiency by comparing three different transfection
reagents showed that TransIT-TKO from Mirus Bio was the transfection reagent of choice
with about 90% transfection efficiency and minimum cell toxicity. This provides
pharmacologists and toxicologists with information that may be helpful when performing
future siRNA studies with primary hepatocytes.

Foreign chemicals as well as endogenous compound are subject to metabolism by a
number of xenobiotic and endobiotics metabolizing enzymes to facilitate their
elimination. CYP2D enzymes are among the most important enzymes responsible for the
oxidative metabolism of a diverse range of substrates (Guengerich, 2003). Thus the last
objective in this study is to test the possibility of using primary hepatocytes as in vitro
model system in metabolism study. Three CYP2D substrates were chosen to test our
model; testosterone, tamoxifen and luminogenic CYP2D6 substrate. In mouse
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testosterone is metabolized by Cyp2d9, Cyp2d10 and Cyp2d11 to 16 hydroxytestosteron (Wong et al., 1989) so the sterio- and regio-specific hydroxylation of
testosterone and the contribution of CYP2D to this effect could be investigated using our
model. A testosterone hydroxylase activity in knockdown and scrambled treated
hepatocytes was measured by thin layer chromatography (TLC). The second tested
substrate was P450-Glo™ CYP2D6 enzyme kits, where a luminogenic CYP2D6
substrate was incubated with S9 fraction from tested cells. The third substrate was
tamoxifen, selective estrogen receptor modulator used for treatment and prevention of
breast cancer (Eberling et al., 2004). In humans, CYP2D6 is involved in tamoxifen
metabolism and 4-OH-tamoxifen and endoxifen are important active metabolites of
tamoxifen (Stearns et al., 2003; Lim et al., 2006). The data from metabolism study
showed that there was no metabolites difference of testosterone, luminogenic CYP2D6
substrate, or tamoxifen between knockdown and wild type hepatocytes. This might be
explained by the remaining functional CYP2Ds protein inside the hepatocytes. To
maintain as much as CYP2D activity, transfection was done only for 24hrs, during this
period; about 50-70% of CYP2Ds mRNA was degraded by siRNA-KD1. However, the
previously translated CYP2Ds protein may be still remaining and functioning in the cells
and may be still able to metabolize those substrates.

For the P450-Glo™ CYP2D6 enzyme kits, because of species differences, the mouse
Cyp2d activity may be different from CYP2D6 and it is possible that murine Cyp2d
isoforms could not metabolize the substrate. Moreover, primary culture has high level of
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esterase activity that affects the substrate stability. A potential explanation of the
inability of our knockdown in vitro model system to show significant difference from the
wild type cells in metabolizing the tested substrates is the marked differences in CYP2D
between humans and experimental animals (Masubuchi et al., 1997). Significant species
differences exist between rodents and humans in expression and catalytic activity
between human CYP2D6 and rodent Cyp2d (Bogaards et al., 2000). This data
demonstrates that the search for a better or known mouse CYP2D specific substrate is
important in evaluating the impaired metabolic profile in the in vitro knockdown model
system.

In conclusion, for the first time, multiple CYP2D were successfully down-regulated in
the mouse primary hepatocytes in an in vitro model using a single siRNA construct. One
potential application of this method is to determine and quantify the role of specific CYPs
in the metabolism of individual drugs. A second could be to study potential
compensatory mechanisms and interactions between CYPs. Third, a long-term potential
goal or application of this work is applying the CYP2D-KD1 siRNA to the in vivo model
system (humanized mouse model) to knockdown the expression of mouse CYP2Ds. This
would be valuable application to reduce the redundant interfering function of mouse
CYP2Ds in those models. Thus this would be a promising application in the
pharmaceutical industry to validate the humanized model system in studying the
CYP2D6 function in polymorphic individuals and avoid the possible ADR in those
individuals.
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Another interesting finding in this study is that Cyp2d10 was over expressed when
Cyp2d-KD2 was used, indicating that Cyp2d10 is inducible. Future directions toward
understanding of the mechanism by which Cyp2ds are regulated and could help elucidate
which transcription factors are needed. However, the loss of Cyp2d9 expression in vitro,
and gradual loss of CYP2D over time suggesting that more efforts are still needed to
develop alternative cellular models that maintain the basal level of CYP2D expression in
vitro. 3D culture could be a possibility.
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